NYSE - Nasdaq Real Time Price USD

Ormat Technologies, Inc. (ORA)

63.42 -1.57 (-2.42%)
As of 12:17 PM EDT. Market Open.

Earnings Estimate

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
No. of Analysts 5555
Avg. Estimate 0.630.392.132.43
Low Estimate 0.470.21.822
High Estimate 0.780.612.472.8
Year Ago EPS 0.510.42.082.13

Revenue Estimate

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
No. of Analysts 5555
Avg. Estimate 218.77M214.04M888.2M974.85M
Low Estimate 201.95M209.5M875.1M901.7M
High Estimate 235M219.49M909.15M1.04B
Year Ago Sales 212.86M194.8M829.42M888.2M
Sales Growth (year/est) 2.80%9.90%7.10%9.80%

Earnings History

CURRENCY IN USD 3/31/2023 6/30/2023 9/30/2023 12/31/2023
EPS Est. 0.490.340.350.59
EPS Actual 0.510.40.590.59
Difference 0.020.060.240
Surprise % 4.10%17.60%68.60%0.00%

EPS Trend

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
Current Estimate 0.630.392.132.43
7 Days Ago 0.630.392.132.43
30 Days Ago 0.630.392.132.43
60 Days Ago 0.570.622.352.48
90 Days Ago 0.70.62.542.85

EPS Revisions

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

CURRENCY IN USD ORAIndustrySectorS&P 500
Current Qtr. 23.50%----1.50%
Next Qtr. -2.50%----11.40%
Current Year 2.40%----5.20%
Next Year 14.10%----13.40%
Next 5 Years (per annum) 32.30%----11.09%
Past 5 Years (per annum) 5.36%------

Research Analysis

Analyst Price Targets

69.00
78.00 Average
63.42 Current
95.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Upgrades & Downgrades

Maintains Barclays: Equal-Weight to Equal-Weight 2/5/2024
Maintains Oppenheimer: Outperform to Outperform 1/19/2024
Maintains JP Morgan: Neutral to Neutral 10/19/2023
Maintains Oppenheimer: Outperform to Outperform 10/12/2023
Upgrade Roth MKM: Neutral to Buy 8/7/2023
Reiterates Oppenheimer: Outperform to Outperform 6/27/2023

Related Tickers